Fusion Looking To Enter Cranial Surgery Sealant Market With Proceed Gel
This article was originally published in The Gray Sheet
Fusion Medical sees a $35 mil. market opportunity for the cranial indication of the firm's Proceed hemostatic sealant, based on a projected per-kit price of $140 and more than 240,000 cranial procedures performed worldwide annually.
You may also be interested in...
Patient enrollment has begun at two sites in a randomized trial of the FloSeal Femoral Arteriotomy Sealing Technology (FAST) device, which is being developed by Fusion Medical for sealing femoral artery punctures created for diagnostic or therapeutic catheterization procedures.
Focal, Inc. should include a warning in labeling for FocalSeal-L synthetic lung surgery sealant that higher risks of infection or empyema may be associated with use of the product, FDA's General and Plastic Surgery Devices Advisory Panel recommended at a May 8 meeting in Gaithersburg, Maryland.
Fusion Medical Technologies commenced shipments of its FloSeal hemostatic sealant on Dec. 9 at a price of $125 for a 4 ml kit, following FDA approval Dec. 8.